Henry Schein 将来の成長

Future 基準チェック /36

Henry Schein利益と収益がそれぞれ年間26.7%と4.5%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に15.2% 21.8%なると予測されています。

主要情報

26.7%

収益成長率

21.8%

EPS成長率

Healthcare 収益成長	27.0%
収益成長率	4.5%
将来の株主資本利益率	15.2%
アナリストカバレッジ	Good
最終更新日	08 Nov 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

BOVESPA:H1SI34 - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	13,896	617	774	1,024	11
12/31/2025	13,349	559	704	905	12
12/31/2024	12,854	422	642	797	13
9/28/2024	12,499	314	421	612	N/A
6/29/2024	12,487	352	495	692	N/A
3/30/2024	12,451	388	473	670	N/A
12/30/2023	12,339	416	313	500	N/A
9/30/2023	12,693	445	587	786	N/A
7/1/2023	12,598	458	480	653	N/A
4/1/2023	12,528	478	387	536	N/A
12/31/2022	12,647	538	474	602	N/A
9/24/2022	12,607	638	528	625	N/A
6/25/2022	12,718	650	648	738	N/A
3/26/2022	12,655	646	656	740	N/A
12/25/2021	12,401	631	598	710	N/A
9/25/2021	12,236	626	723	783	N/A
6/26/2021	11,898	606	783	833	N/A
3/27/2021	10,615	438	544	583	N/A
12/26/2020	10,119	403	550	599	N/A
9/26/2020	9,622	591	477	542	N/A
6/27/2020	9,291	585	436	512	N/A
3/28/2020	10,054	713	683	766	N/A
12/28/2019	9,986	701	578	654	N/A
9/28/2019	9,789	488	585	655	N/A
6/29/2019	9,636	444	526	597	N/A
3/30/2019	9,504	438	648	722	N/A
12/29/2018	9,418	431	613	685	N/A
9/29/2018	10,263	304	553	629	N/A
6/30/2018	11,069	352	N/A	586	N/A
3/31/2018	11,812	377	N/A	527	N/A
12/30/2017	8,883	293	N/A	546	N/A
9/30/2017	12,264	554	N/A	572	N/A
7/1/2017	11,968	550	N/A	619	N/A
4/1/2017	11,782	534	N/A	668	N/A
12/31/2016	11,572	507	N/A	643	N/A
9/24/2016	11,302	498	N/A	676	N/A
6/25/2016	11,122	492	N/A	605	N/A
3/26/2016	10,879	489	N/A	536	N/A
12/26/2015	10,630	479	N/A	616	N/A
9/26/2015	10,481	482	N/A	563	N/A
6/27/2015	10,419	469	N/A	630	N/A
3/28/2015	10,405	467	N/A	621	N/A
12/27/2014	10,371	466	N/A	593	N/A
9/27/2014	10,196	457	N/A	593	N/A
6/28/2014	9,921	450	N/A	571	N/A
3/29/2014	9,697	442	N/A	647	N/A
12/28/2013	9,561	432	N/A	664	N/A

アナリストによる今後の成長予測

収入対貯蓄率: H1SI34の予測収益成長率 (年間26.7% ) は貯蓄率 ( 10.4% ) を上回っています。

収益対市場: H1SI34の収益 ( 26.7% ) はBR市場 ( 12.6% ) よりも速いペースで成長すると予測されています。

高成長収益: H1SI34の収益は今後 3 年間で大幅に増加すると予想されています。

収益対市場: H1SI34の収益 ( 4.5% ) BR市場 ( 7.4% ) よりも低い成長が予測されています。

高い収益成長: H1SI34の収益 ( 4.5% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: H1SI34の自己資本利益率は、3年後には低くなると予測されています ( 15.2 %)。

Henry Schein 将来の成長

Future 基準チェック /36

主要情報

今後の成長に関する最新情報

Henry Schein, Inc. Updates Earnings Guidance for the Full Year 2024

Henry Schein, Inc. Revises Earnings Guidance for the Year 2024

Henry Schein, Inc. Revises Earnings Guidance for the Year 2024

Henry Schein, Inc. Provides Earnings Guidance for 2023

Henry Schein, Inc. Affirms Earnings Guidance for the Full Year of 2023

Henry Schein, Inc. Provides Sales Guidance for the Fiscal Year 2023

Recent updates

Henry Schein, Inc. (NasdaqGS:HSIC) signed an agreement to acquire Acentus.

Ananym Capital Management Pushes for Changes at Henry Schein

Ananym Capital Management Pushes for Changes at Henry Schein

Henry Schein, Inc. Updates Earnings Guidance for the Full Year 2024

Henry Schein, Inc. to Report Q3, 2024 Results on Nov 05, 2024

Henry Schein, Inc.(NasdaqGS:HSIC) dropped from FTSE All-World Index (USD)

Henry Schein, Inc. Revises Earnings Guidance for the Year 2024

Henry Schein, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Henry Schein, Inc. Revises Earnings Guidance for the Year 2024

Henry Schein, Inc. to Report Q1, 2024 Results on May 07, 2024

Henry Schein, Inc. Announces Appointment of Members to the Company’S Executive Management Committee

Henry Schein, Inc. (NasdaqGS:HSIC) completed the acquisition of an unknown majority interest in TriMed, Inc.

Henry Schein, Inc., Annual General Meeting, May 21, 2024

Henry Schein, Inc. Presents Comprehensive Lineup of Solutions At the 2024 Chicago Dental Society Mid Winter Meeting

Henry Schein, Inc. Presents Comprehensive Lineup of Solutions At the 2024 Chicago Dental Society Mid Winter Meeting

Henry Schein, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Henry Schein, Inc. (NasdaqGS:HSIC) signed an agreement to acquire an unknown majority interest in TriMed, Inc.

Henry Schein Appoints Carole T. Faig as New Independent Director

Henry Schein Announces Receipt of Deficiency Notice From Nasdaq Regarding Requirement to Timely File Quarterly Report on Form 10-Q

Henry Schein Announces Receipt of Deficiency Notice From Nasdaq Regarding Requirement to Timely File Quarterly Report on Form 10-Q

Henry Schein, Inc. Provides Earnings Guidance for 2023

Henry Schein, Inc. announced delayed 10-Q filing

Henry Schein, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Henry Schein, Inc. (NasdaqGS:HSIC) completed the acquisition of an unknown majority stake in Shield HealthCare, Inc.

Henry Schein, Inc. Affirms Earnings Guidance for the Full Year of 2023

Henry Schein, Inc. (NasdaqGS:HSIC) signed an agreement to acquire a majority stake in Shield HealthCare, Inc.

Henry Schein, Inc. (NasdaqGS:HSIC) acquired a majority stake in Large Practice Sales LLC.

Henry Schein, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Henry Schein, Inc. Provides Sales Guidance for the Fiscal Year 2023

Henry Schein, Inc. (NasdaqGS:HSIC) acquired Regional Healthcare Group Pty Ltd.

Henry Schein, Inc. (NasdaqGS:HSIC) acquired Regional Healthcare Group Pty Ltd.

Henry Schein, Inc. (NasdaqGS:HSIC) agreed to acquire SIN - Sistema de Implante Nacional S.A. from Southern Cross Group.

Henry Schein, Inc. Reports Impairment Charge on Intangible Assets for the Fourth Quarter Ended December 31, 2022

Henry Schein, Inc. (NasdaqGS:HSIC) announces an Equity Buyback for $400 million worth of its shares.

Henry Schein, Inc. to Report Q4, 2022 Results on Feb 16, 2023

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘